AI Summary
An FDA panel rejected NurOwn, a stem cell therapy for ALS.
An FDA advisory panel resoundingly rejected NurOwn, an experimental stem cell therapy for mild to moderate ALS.
Medscape Medical News
FDA Panel Rejects Experimental Stem Cell Therapy for ALS
